drugset / Trial / NCT02485028

Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg

NCT02485028

Phase 1 Completed 36 enrolled SK Chemicals Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 50mg for three times, respectively and the pharmacokinetic interaction was compared between the two drugs.

Timeline

Start
2013-10
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapoxetine Small molecule 30 mg
Subject Mirodenafil Small molecule 50 mg

Indications

No indication recorded.